申请人:PHARMACIA S.p.A.
公开号:EP0558950A1
公开(公告)日:1993-09-08
The present invention relates to 3-aryl-oxirane derivatives of formula
wherein
Ar is a mono- or bicyclic ring system chosen from naphthalene, 5', 6', 7', 8'-tetrahydronaphthalene, quinoline and indole;
each of R and R₁ independently is hydrogen or a substituent chosen from halogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₂-C₆ acyloxy, cyano and nitro;
one of X and Y is hydrogen, cyano, -COOR₂ or -CONR₃R₄ in which R₂ is C₁-C₆ alkyl and each of R₃ and R₄ independently is hydrogen or C₁-C₆ alkyl, and the other one of X and Y independently is cyano, -COOR₂ or CONR₃R₄ wherein R₂, R₃ and R₄ are as defined above, and the pharmaceutically acceptable salts thereof, which are useful in therapy as tyrosine kinase inhibitors,in particular as anti-proliferative agents and in the treatment of coronary artery disease.
本发明涉及式 3-芳基环氧乙烷衍生物
其中
Ar 是选自萘、5'、6'、7'、8'-四氢萘、喹啉和吲哚的单环或双环系统;
R 和 R₁ 中各自独立地为氢或选自卤素、羟基、C₁-C₆ 烷基、C₁-C₆ 烷氧基、C₂-C₆酰氧基、氰基和硝基的取代基;
X 和 Y 中的一个是氢、氰基、-COOR₂ 或 -CONR₃R₄,其中 R₂ 是 C₁-C₆ 烷基,R₃ 和 R₄ 各自独立地是氢或 C₁-C₆ 烷基、X 和 Y 中的另一个独立地为氰基、-COOR₂ 或 CONR₃R₄,其中 R₂、R₃和 R₄如上所定义,及其药学上可接受的盐类,可作为酪氨酸激酶抑制剂,特别是作为抗增殖剂和治疗冠状动脉疾病的药物。